Biomarkers Identified for Irritable Bowel Syndrome
|
By LabMedica International staff writers Posted on 02 May 2018 |

Image: The nanoLC-Ultra 1D+ for nanoflow liquid chromatography (Photo courtesy of Eksigent).
The causes of gastrointestinal complaints in irritable bowel syndrome (IBS) remain poorly understood. Altered nerve function has emerged as an important pathogenic factor as IBS mucosal biopsy supernatants consistently activate enteric and sensory neurons.
The enteric nervous system (ENS) in the gut wall coordinates and maintains normal gut functions. Its central role for normal motility, secretion and immune cell function also indicates that altered ENS function is often associated with gut pathologies. Irritable bowel syndrome (IBS) is a functional gastrointestinal disease and belongs with a population prevalence of ~11% to the most common gut disorders.
An international team of scientists led by those at the Technical University of Munich (Freising, Germany) studied the effect of supernatants from seven healthy controls (HC), 20 IBS and 12 ulcerative colitis (UC) patients on human and guinea pig submucous neurons were studied with neuroimaging techniques. They identified differentially expressed proteins with proteome analysis. Macroscopically normal intestinal specimens (as determined by visual inspection by a pathologist) were taken from 105 patients (51 male, 54 female, mean age 69 years) who underwent surgery for various pathologies.
Analysis of imaging studies was performed with Neuroplex 10.1.2. Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed by coupling an Eksigent nanoLC-Ultra 1D+ to an Orbitrap Elite mass spectrometer.
The team found that for the nerve activating properties of IBS and UC supernatants were mainly due to proteases, which are not only enzymes but also important signaling molecules. However, there was an important difference. While the nerve activation from IBS supernatants was mediated by proteases signaling via the protease activated receptor type 1, this receptor played no role in the effect of UC supernatants. They found an IBS-specific protein pattern, in particular an IBS-specific protease profile. Proteome analysis revealed 204 differently expressed proteins in IBS supernatants and four proteases that were only enhanced in IBS supernatants.
The team addressed the translational relevance of the finding by asking the question how they could influence the nerve activation, besides using PAR1 blockers. They reported that using a protease inhibitor from a probiotic Bifidobacterium longum strain, this inhibitor blocked the nerve activation triggered by the IBS supernatant. The study was published on March 12, 2018, in the journal Public Library of Science ONE.
Related Links:
Technical University of Munich
The enteric nervous system (ENS) in the gut wall coordinates and maintains normal gut functions. Its central role for normal motility, secretion and immune cell function also indicates that altered ENS function is often associated with gut pathologies. Irritable bowel syndrome (IBS) is a functional gastrointestinal disease and belongs with a population prevalence of ~11% to the most common gut disorders.
An international team of scientists led by those at the Technical University of Munich (Freising, Germany) studied the effect of supernatants from seven healthy controls (HC), 20 IBS and 12 ulcerative colitis (UC) patients on human and guinea pig submucous neurons were studied with neuroimaging techniques. They identified differentially expressed proteins with proteome analysis. Macroscopically normal intestinal specimens (as determined by visual inspection by a pathologist) were taken from 105 patients (51 male, 54 female, mean age 69 years) who underwent surgery for various pathologies.
Analysis of imaging studies was performed with Neuroplex 10.1.2. Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed by coupling an Eksigent nanoLC-Ultra 1D+ to an Orbitrap Elite mass spectrometer.
The team found that for the nerve activating properties of IBS and UC supernatants were mainly due to proteases, which are not only enzymes but also important signaling molecules. However, there was an important difference. While the nerve activation from IBS supernatants was mediated by proteases signaling via the protease activated receptor type 1, this receptor played no role in the effect of UC supernatants. They found an IBS-specific protein pattern, in particular an IBS-specific protease profile. Proteome analysis revealed 204 differently expressed proteins in IBS supernatants and four proteases that were only enhanced in IBS supernatants.
The team addressed the translational relevance of the finding by asking the question how they could influence the nerve activation, besides using PAR1 blockers. They reported that using a protease inhibitor from a probiotic Bifidobacterium longum strain, this inhibitor blocked the nerve activation triggered by the IBS supernatant. The study was published on March 12, 2018, in the journal Public Library of Science ONE.
Related Links:
Technical University of Munich
Latest Pathology News
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








